Future research should focus on validating these drug synergies in preclinical and clinical settings to optimize therapeutic strategies and improve outcomes for patients with HER2+ breast cancer, which may even open the door for treatments for other types of neoplasies. Here, ERBB2 is linked to breast carcinoma.